Ethris GmbH

20 patents currently held · Updated Nov 14, 2026

5 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Dec 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Sep 10, 2027
The maintenance fee for Conjugate with Target-Finding Ligand and Use Thereof (US 10,583,195) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026
1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,555,122	Conjugate With Target-Finding Ligand and Use Thereof In force Ends no later than Dec 21, 2030 · Medium confidence	In force	Ends no later than Dec 21, 2030	Medium confidence
US 10,583,195	Conjugate with Target-Finding Ligand and Use Thereof In force Term ends Dec 21, 2030 · Medium confidence	In force	Term ends Dec 21, 2030	Medium confidence
US 10,745,698	RNA with a combination of unmodified and modified nucleotides for protein expression In force Term ends Jan 22, 2032 · From the USPTO record	In force	Term ends Jan 22, 2032	From the USPTO record
US 11,090,264	Pulmonary Delivery of Mrna to Non-Lung Target Cells In force Term ends Jun 7, 2033 · High confidence	In force	Term ends Jun 7, 2033	High confidence
US 12,064,484	Compositions for introducing RNA into cells In force Term ends Jun 27, 2034 · From the USPTO record	In force	Term ends Jun 27, 2034	From the USPTO record
US 10,272,161	RNA for Use in the Treatment of Ligament or Tendon Lesions In force Term ends Jul 16, 2035 · High confidence	In force	Term ends Jul 16, 2035	High confidence
US 11,065,346	RNA for use in the treatment of ligament or tendon lesions In force Ends no later than Jul 16, 2035 · From the USPTO record	In force	Ends no later than Jul 16, 2035	From the USPTO record
US 12,263,229	Induction of osteogenesis by delivering BMP encoding RNA In force Term ends Nov 10, 2035 · From the USPTO record	In force	Term ends Nov 10, 2035	From the USPTO record
US 12,594,295	CFTR Mrna Compositions and Related Methods and Uses In force Term ends Mar 3, 2036 · Medium confidence	In force	Term ends Mar 3, 2036	Medium confidence
US 11,479,768	ATP-binding cassette family coding polyribonucleotides and formulations thereof In force Term ends Jun 30, 2036 · From the USPTO record	In force	Term ends Jun 30, 2036	From the USPTO record

10 of 20 patents shown.

Pro members see all 20.

Pro members: see all 20 patents

Also on record, not counted in the 20: 5 patents in force now held by others · 2 lapsed for an unpaid fee · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 1 abandoned · 9 no status recorded

List them